• Explore /
  • Poster
  • / Cabozantinib in patients with locally advanced or metastatic urothelial cell carcinoma who have progressed after cisplatin-based chemotherapy and anti-PD-1/PD-L1 therapy or after anti-PD-1/PD-L1 therapy only.

Cabozantinib in patients with locally advanced or metastatic urothelial cell carcinoma who have progressed after cisplatin-based chemotherapy and anti-PD-1/PD-L1 therapy or after anti-PD-1/PD-L1 therapy only.

Abstract Poster

Authors

null

Georg Bartsch

Markus Krankenhaus, Frankfurt Am Main, RI, Germany

Georg Bartsch , Christian Thomas , Igor Tsaur , Marco Schnabel , Axel Haferkamp , Stanislav Gorbulev , Christian Ruckes , Kai Kronfeld

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer and Urothelial Carcinoma

Track

Urothelial Carcinoma,Prostate Cancer - Advanced

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04066595

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 525)

DOI

10.1200/JCO.2023.41.6_suppl.525

Abstract #

525

Poster Bd #

L8

Abstract Disclosures

Similar Posters

First Author: Roberto Iacovelli

First Author: Josep Tabernero

First Author: Arvind Chaudhry

First Author: Amit Bahl